Andrea Tu, Author at Bolt Biotherapeutics

Press Release

Bolt Biotherapeutics Prices Upsized Initial Public Offering

By Andrea Tu|2021-02-05T07:25:01-08:00February 5, 2021|press release|Comments Off

Bolt Biotherapeutics Expands Board of Directors with Appointment of Kathleen [...]

By Andrea Tu|2021-02-04T14:47:03-08:00January 3, 2021|press release|Comments Off

Bolt Biotherapeutics Presents Ongoing Clinical Trial Poster at San Antonio [...]

By Andrea Tu|2021-02-04T14:47:43-08:00December 9, 2020|press release|Comments Off

Data Published in Nature Cancer Highlight Preclinical Proof of Concept [...]

By Andrea Tu|2021-02-04T14:48:13-08:00December 7, 2020|press release|Comments Off

Dr. Randy Schatzman On Dodging Disruption: The New Fundraising Norm [...]

By Andrea Tu|2020-09-22T21:40:36-07:00September 21, 2020|podcast|Comments Off

Bolt Biotherapeutics Presents BDC-1001 Ongoing Clinical Trial Design and Supportive [...]

By Andrea Tu|2021-01-03T21:36:16-08:00September 20, 2020|press release|Comments Off

Bolt Biotherapeutics Closes $93.5 Million Series C Financing

By Andrea Tu|2020-11-10T12:16:17-08:00August 1, 2020|press release|Comments Off

CMC Considerations For In-Human Studies with Drs. Edith Perez and [...]

By Andrea Tu|2020-11-10T12:15:49-08:00July 22, 2020|podcast|Comments Off

Randy Schatzman, PhD, CEO of Bolt Biotherapeutics Biotech 2050 Podcast

By Andrea Tu|2020-11-10T12:14:18-08:00July 21, 2020|podcast|Comments Off

Bolt Bio Adds $93.5M to Move Ahead Immune-Stimulating Cancer Drugs [...]

By Andrea Tu|2020-11-10T12:12:52-08:00July 7, 2020|media coverage|Comments Off